Phaseline

Targets › GALC

GALC (Galactocerebrosidase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jun 2028.

Lysosomal hydrolase that removes the terminal galactose from galactosylceramide, a major lipid of the myelin sheath, kidney, and epithelial cells of the small intestine and colon, and from related glycosphingolipids such as galactosylsphingosine. Present at very low abundance/specific activity in tissues relative to other lysosomal enzymes. (UniProt, P54803)

Open in Phaseline: the race on GALC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Duke UniversityFBX-101
AAVrh.10 vector expressing human galactocerebrosidase (GALC) cDNA
GALCPhase 1Krabbe DiseaseJun 2028

Conditions

Krabbe Disease (1)

Modalities

protein or peptide (1)

Companies

Duke University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.